Conjunctivitis Treatment Market size was over USD 5.22 Billion in 2023 and is projected to exceed USD 9.02 Billion by the end of 2036, witnessing over 4.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of conjunctivitis treatment is evaluated at USD 5.44 Billion. The growth of the market can be attributed to the increasing prevalence of infectious conjunctivitis disease across the world, along with the development & advancements in drug delivery methods for conjunctivitis treatment. Furthermore, there has been a surge in the number of bacteria and viruses that can affect the conjunctiva, and it is anticipated to boost the growth of the global conjunctivitis treatment market. For instance, as per the observations, the occurrence of conjunctivitis infection in the last 10 years was recognized in more than 20% of participants across the world.
In addition to these, factors that are believed to fuel the market growth of conjunctivitis treatment include the rising development & advancements in drug delivery methods for conjunctivitis treatment, coupled with technological advancements in ophthalmology treatment. Moreover, a significant rise in healthcare expenditure is also predicted to present the potential for market expansion over the projected period. For instance, the healthcare expenditure of the U.S. in 2020 rose to 9.7% and reached USD 4.1 trillion i.e., USD 12,530 per individual. Additionally, an upsurge in novel drug formulations and rising awareness among people regarding eye diseases is another significant factor that is projected to fuel the market growth throughout the forecast period.
Growth Drivers
Increasing Air Pollution Across the World – Exposure to indoor or outdoor air pollution can be harmful to human eyes. Tobacco smoking, cooking, and poor indoor ventilation cause eye disorders such as glaucoma, conjunctivitis, cataracts, and age-related macular degeneration. For instance, air pollution accounts for 12% of deaths in the world, and air pollution from particulate matter 2.5 leads to allergic conjunctivitis and glaucoma.
Rising Burden of Bacterial Conjunctivitis Infection - There are various ways that bacterial conjunctivitis can spread from person to person. These include cross-transmission from mother to child or hand-to-eye contact as well as eye contact with contaminated objects. Large respiratory tract droplets are another way through which bacteria can spread. Conjunctivitis can also result from mutations in the conventional bacteria that inhabit the conjunctiva. Thus, the surging burden of bacterial conjunctivitis infection is another factor that is estimated to fuel the growth of the global conjunctivitis treatment market in the coming years. For instance, the cost of treatment in the U.S. for only bacterial conjunctivitis is around USD 370-850 million per year.
Growing Globalization and Industrialization – The number of industries across the globe grew from 320 million in 2020 to 330 million in 2021, as per the estimations.
Rising Cases of Neonatal Conjunctivitis – In the United States, Ophthalmia neonatorum was one of the common conditions seen in nearly 1% to 12% of neonates in 2022.
Elevating Ratio of Sexually Transmitted Infections (STIs) – As per the World Health Organization figures, each day, over 1 million sexually transmitted infections (STIs) are acquired throughout the world, a large percentage of which show no symptoms.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
4.3% |
|
Base Year Market Size (2023) |
USD 5.22 Billion |
|
Forecast Year Market Size (2036) |
USD 9.02 Billion |
|
Regional Scope |
|
Drug Class (Antibiotics, Antiviral, Antiallergic, Artificial Tears)
The global conjunctivitis treatment market is segmented and analyzed for demand and supply by drug class into antibiotics, antiviral, antiallergic, artificial tears, and others. Out of these types of segments, the antiallergic segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing use of antiallergic drugs in allergic reactions as these drugs provide faster relief and recovery in such diseases, along with the growing prevalence of allergies among people, especially those who are prone to seasonal allergies. For instance, allergic conjunctivitis or allergic eye issue was seen in 40% of people in the United States in 2020.
Disease Type (Bacterial, Chemical, Viral, Allergic Conjunctivitis)
The global conjunctivitis treatment market is also segmented and analyzed for demand and supply by disease type into bacterial conjunctivitis, chemical conjunctivitis, viral conjunctivitis, and allergic conjunctivitis. Amongst these segments, the allergic conjunctivitis segment is expected to garner a significant share. The segment is anticipated to grow owing to the surging prevalence of allergic conjunctivitis. In addition to this, an upsurge in the novel product launches for the effective treatment of this disease is another major factor that is anticipated to propel the market growth. On the other hand, the viral conjunctivitis segment is projected to witness a moderate CAGR during the forecast period, owing to the surge in contagious virus spread as a result of the common cold.
Route of Administration (Oral, Topical)
On the other hand, the global conjunctivitis treatment market is also segmented and analyzed for demand and supply by route of administration into oral, and topical. Amongst these two segments, the topical segment is projected to grasp a notable market share. The growth of the segment can be attributed to the formulation and launch of novel drugs that can be easily used and deliver effective treatment. For instance, in March 2022, Visus Therapeutics Inc. announced the commencement of the first of two important phases 3 trials (BRIO-I and BRIO-II) for its flagship asset, BRIMOCHOL PF, a topical preservative-free ophthalmic liquid for the treatment of presbyopia.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Disease Type |
|
|
By Route of Administration |
|
|
By End-User |
|
North American Market Forecast
The North America conjunctivitis treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the increasing occurrence of conjunctivitis, coupled with the growing use of corrective lenses by individuals in the region. For instance, as per the estimations, in the United States, nearly 60% of people aged 26-40 and 90% of people aged 70 wear corrective lenses. Hyperopia, astigmatism, myopia, and presbyopia treatment are typically done with the corrective lenses. In addition, corrective lenses are designed to assist the eyes in properly focusing light onto the retinas so that an individual can see properly. Further, the presence of a strong healthcare infrastructure in the region, along with the presence of major key players, is also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare expenditure and rising advancements in conjunctivitis treatment are also anticipated to boost market growth during the forecast period.
APAC Market Statistics
Furthermore, the Asia Pacific conjunctivitis treatment market is projected to display faster growth over the forecast period on the back of the escalating count of research and development activities, coupled with the increasing healthcare expenditure in the region. Based on the World Bank statistics, health expenditure in East Asia and the Pacific increased from 6.51% of total GDP in 2018 to 6.67% of GDP in 2019. Besides this, the surging ratio of aged patients, along with the development of healthcare facilities in the region are also projected to accelerate the market growth further throughout the forecast period in the APAC region.
Novartis AG acquired Kedalion Therapeutics and its AcuStream technology, a novel device to improve the Novartis ophthalmic portfolio.
AbbVie Inc. declared the U.S. Food and Drug Administration (FDA) approval of VUITY, a pilocarpine HCl ophthalmic solution of 1.25 % used for the treatment of presbyopia that affects 128 million Americans.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?